Moonlake Immunotherapeutics AG
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 2021-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.moonlaketx.com
Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 960
- Registration Number
- NCT06641076
- Locations
- 🇺🇸
Clinical Site, Grapevine, Texas, United States
Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 600
- Registration Number
- NCT06641089
- Locations
- 🇺🇸
Clinical Site, Lubbock, Texas, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 400
- Registration Number
- NCT06411899
- Locations
- 🇬🇧
Clinical Site, Dudley, United Kingdom
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 400
- Registration Number
- NCT06411379
- Locations
- 🇪🇸
Clinical Site, Santiago De Compostela, Spain
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 207
- Registration Number
- NCT05640245
- Locations
- 🇵🇱
Clinical SIte, Wrocław, Poland
🇪🇸Clinical Site, Sevilla, Spain
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 234
- Registration Number
- NCT05322473
- Locations
- 🇵🇱
Clinical Site, Łódź, Poland
© Copyright 2024. All Rights Reserved by MedPath